Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.

In this article, we are going to take a look at where MoonLake Immunotherapeutics (NASDAQ:MLTX) stands against the other oversold biotech stocks to buy now. Biotechnology stocks are among the most ...

MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day MoonLake further announces ...

MoonLake Immunotherapeutics is a Cayman Islands domiciled, Zug, Switzerland headquartered clinical-stage biopharmaceutical concern focused on the development of its sonelokimab (SLK) therapy to ...

Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases ...

ZUG, Switzerland, July 25, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory ...

This increases the number of clinical trials led by MoonLake to ten and aligns with the plan to enroll over 3,000 patients in clinical trials with sonelokimab since the Company was founded in 2021.

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppura ...